HBM Holdings Limited (2142.HK)

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.